| Biomarker ID | 242 |
| PMID | 18196514 |
| Year | 2008 |
| Biomarker | CXCL12 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Upregulated in Biopsy Positive Patients |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Binding of chemokines to chemokine receptors, Nuclear signaling by ErbB4,Intestinal immune network for IgA production,HIF-1 transcriptional activity in hypoxia,Interleukin-7 interactions in immune response |
| Experiment | Biopsy Negative Patients And Biopsy Positive Patients for Prostate Cancer |
| Type of Biomarker | Diagnostic |
| Cohort | 51 men were included in this study. 25 men presented with BPH (17 with negative biopsies and 8 with positive biopsies). 14 were detected with Prostate Cancer. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.05 |
| Method Used | Sandwich ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | CXCL12 |